Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that is in Phase III study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It is also developing a range of small-molecule product candidates, such as UX007, a substrate replacement therapy that completed Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome. In addition, the company is developing adeno-associated virus 8 (AAV8) gene therapy products comprising DTX301, an AAV8 for the treatment of OTC deficiency; DTX401, an AAV8 gene therapy program for the treatment of patients with GSDIa; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. It has a collaboration agreement with Rentschler Fill Solutions GmbH. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-483-8800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$51.49 million
Profitability
Miscellaneous
Employees520
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable
Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions
What is Ultragenyx Pharmaceutical's stock symbol?
Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."
How were Ultragenyx Pharmaceutical's earnings last quarter?
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) issued its quarterly earnings data on Tuesday, February, 19th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.74) by $0.01. The biopharmaceutical company earned $16.26 million during the quarter, compared to analysts' expectations of $13.30 million. Ultragenyx Pharmaceutical had a negative return on equity of 34.15% and a negative net margin of 383.75%. View Ultragenyx Pharmaceutical's Earnings History.
When is Ultragenyx Pharmaceutical's next earnings date?
What price target have analysts set for RARE?
17 Wall Street analysts have issued 1 year price objectives for Ultragenyx Pharmaceutical's stock. Their forecasts range from $59.00 to $95.00. On average, they anticipate Ultragenyx Pharmaceutical's stock price to reach $78.3125 in the next twelve months. This suggests a possible upside of 32.7% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical.
What is the consensus analysts' recommendation for Ultragenyx Pharmaceutical?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical.
What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?
Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Ultragenyx is encouraged by the growing demand for Crysvita from both children and adults with X-linked hypophosphatemia (XLH) inthe United States. During the third quarter, Mepsevii received European approval under exceptional circumstances for the treatment of non-neurological manifestations of MPS VII. In 2019, the company expects to file for potential approval of its third therapy, UX007 in fatty acid oxidation disorders. Ultragenyx continues to advance its two gene therapy clinical programs —DTX401 for glycogen storage disease type Ia and DTX301 for ornithine transcarbamylase deficiency—with additional data expected around the end of 2018 and in 2019 respectively. However, the company plans to discontinue the study, evaluating UX007 in patients with Glut1 DS, as it did not achieve its primary endpoint, which does not bode well for the company. Loss estimates have remained stable ahead of the Q4 earnings release." (1/17/2019)
- 2. JPMorgan Chase & Co. analysts commented, "Ahead of the pending Phase 3 results for UX007 (trihep) in Glut1 DS expected sometime this quarter, we sifted through early data and market sizing assumptions to frame expectations and potential upside/downside on the event. Bottom line, while directly comparable data are limited to say the least (most similar pilot study only had an N of 6 and Phase 2 trials evaluated different endpoints), we believe a positive read- out is the most likely outcome given proof of concept data combined with seemingly reasonable powering assumptions. Between the recent pullback in shares (15% since 9/25) and our sense that this opportunity is not well understood by the market, we see risk/reward slightly skewed to the upside. Maintain OW." (10/7/2018)
Has Ultragenyx Pharmaceutical been receiving favorable news coverage?
News stories about RARE stock have trended somewhat positive this week, according to InfoTrie. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ultragenyx Pharmaceutical earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the immediate future.
Who are some of Ultragenyx Pharmaceutical's key competitors?
Some companies that are related to Ultragenyx Pharmaceutical include Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Beigene (BGNE), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Dr.Reddy's Laboratories (RDY) and Amarin (AMRN).
What other stocks do shareholders of Ultragenyx Pharmaceutical own?
Who are Ultragenyx Pharmaceutical's key executives?
Ultragenyx Pharmaceutical's management team includes the folowing people:
- Dr. Emil D. Kakkis, Pres, CEO & Director (Age 59)
- Ms. Shalini Sharp, CFO & Exec. VP (Age 44)
- Mr. Thomas R. Kassberg, Chief Bus. Officer & Exec. VP (Age 59)
- Mr. John Richard Pinion II, Chief Quality Officer & Exec. VP of Translational Sciences (Age 53)
- Dr. Wladimir Hogenhuis, Chief Operating Officer
Who are Ultragenyx Pharmaceutical's major shareholders?
Ultragenyx Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.85%), First Trust Advisors LP (2.91%), Northern Trust Corp (1.15%), Geode Capital Management LLC (1.12%), Macquarie Group Ltd. (0.70%) and D. E. Shaw & Co. Inc. (0.64%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.
Which institutional investors are selling Ultragenyx Pharmaceutical stock?
RARE stock was sold by a variety of institutional investors in the last quarter, including WS Management Lllp, Fosun International Ltd, MetLife Investment Advisors LLC, Bellevue Group AG, New York State Common Retirement Fund, California Public Employees Retirement System, Strs Ohio and Zacks Investment Management. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Insider Buying and Selling for Ultragenyx Pharmaceutical.
Which institutional investors are buying Ultragenyx Pharmaceutical stock?
RARE stock was acquired by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., First Trust Advisors LP, BlackRock Inc., Hudson Bay Capital Management LP, Macquarie Group Ltd., Dimensional Fund Advisors LP, Geode Capital Management LLC and Squarepoint Ops LLC. View Insider Buying and Selling for Ultragenyx Pharmaceutical.
How do I buy shares of Ultragenyx Pharmaceutical?
Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ultragenyx Pharmaceutical's stock price today?
One share of RARE stock can currently be purchased for approximately $59.03.
How big of a company is Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical has a market capitalization of $2.99 billion and generates $51.49 million in revenue each year. The biopharmaceutical company earns $-302,130,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis. Ultragenyx Pharmaceutical employs 520 workers across the globe.
What is Ultragenyx Pharmaceutical's official website?
How can I contact Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]
MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
